Table 1.
Summary of patient characteristics
| Characteristic | Number of patients (%) |
|---|---|
| Total | 200 (100.0) |
| Age range (years) | 7‐88 |
| Median age (years) | 58.0 |
| Mean age (years) | 54.7 |
| >60 | 118 (59.0) |
| ≤60 | 82 (41.0) |
| Gender | |
| Male | 109 (54.5) |
| Female | 91 (45.5) |
| Ann Arbor stage | |
| I‐II | 116 (58.0) |
| III‐IV | 84 (42.0) |
| ECOG PS | |
| 0‐1 | 158 (79.0) |
| ≥2 | 42 (21.0) |
| LDH level | |
| Normal | 75 (37.5) |
| Elevated | 125 (62.5) |
| Extranodal involvement | |
| <2 | 156 (78.0) |
| ≥2 | 44 (22.0) |
| B symptoms | |
| Yes | 86 (43.0) |
| No | 114 (57.0) |
| Bulky tumora | |
| Yes | 39 (19.5) |
| No | 161 (80.5) |
| IPI | |
| 0‐2 | 143 (71.5) |
| 3‐5 | 57 (28.5) |
| GC phenotype | |
| GC type | 67 (33.5) |
| Non‐GC type | 133 (66.5) |
| Ki‐67 | |
| <80% | 117 (58.5) |
| ≥80% | 83 (41.5) |
| Treatment | |
| CHOP | 118 (59.0) |
| R‐CHOP | 82 (41.0) |
| Response | |
| CR | 82 (41.0) |
| PR SD, PD | 118 (59.0) |
CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CR, complete remission; ECOG, Eastern Cooperative Oncology Group; GC, germinal center; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PD, progressive disease; PR, partial remission; PS, performance status; R‐CHOP, rituximab CHOP; SD, stable disease.
a
Bulky tumor means the maximum diameter of the tumor is more than 7.5 cm.